You are here: Industry Insights > Hetero

News List

Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China prnasia
November 12, 2021
Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced that they have received import drug license...
Ramp up remdesivir manufacturing to full capacity: Govt to pharma firms expresspharma
April 09, 2021
Mansukh Mandaviya said seven manufacturers - Mylan, Hetero, Jubiliant Life Sciences, Cipla, Dr Reddy's, Zydus Cadila and Sun Pharma - have a monthly production capacity of 31.60 lakh vials.
RDIF and Hetero agree to produce over 100 million doses of Sputnik V vaccine in India expresspharma
November 27, 2020
The parties intend to start the production of Sputnik V in the beginning of 2021.
Hetero launches generic favipiravir to treat Covid-19 in India pharmaceutical-technology
July 31, 2020
India-based Hetero Labs has launched a generic version of antiviral drug favipiravir, under the brand name Favivir, to treat Covid-19 patients in the country.
Hetero launches Favivir to treat mild to moderate Covid-19 expresspharma
July 30, 2020
Favivir, priced at Rs 59 per tablet, will be available at all retail medical outlets and hospital pharmacies across the country but will be sold only on prescription.
Hetero to supply 60,000 vials of generic Remdesvir from July 13 expresspharma
July 16, 2020
Out of 60,000 vials, Maharashtra, which has the highest number of COVID-19 cases in the country will get 12,500 followed by Delhi and Telangana with 10,000 and 9,000 respectively.
Hetero announces launch of generic remdesivir ‘COVIFOR’ for COVID-19 treatment expresspharma
June 22, 2020
COVIFOR will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
Hetero launches HumiraTM biosimilar in India biospectrumasia
January 04, 2018
Hetero unleashes HumiraTM biosimilar in India Hetero did not disclose the price at which it would be marketing the drug in the country